### STATUTORY INSTRUMENTS

# 2019 No. 481

The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2019

# PART 4

## **Transitional Provision**

- **4.**—(1) For a period of six months beginning with [FIIP completion day] the requirements of the provisions listed in paragraph (2) do not apply to—
  - (a) an import of tissues or cells into [F2Great Britain] from an EEA state or Gibraltar;
- (b) an export of tissues or cells from [F3Great Britain] into an EEA state or Gibraltar, provided that the Authority is satisfied that the import or, as the case may be, export meets the requirements of traceability and standards of quality and safety equivalent to those laid down in the Regulations.
  - (2) The provisions referred to in paragraph (1) are—
    - (a) regulation 11(4A) to (4C) of the Regulations.
    - (b) Schedule 2 to the Regulations.
  - (3) In this regulation—
    - (a) "the Regulations" means the Human Tissue (Quality and Safety for Human Application) Regulations 2007; and
    - (b) the terms "the Authority", "cells", "tissue" and "traceability" have the same meanings as they have in the Regulations.

### **Textual Amendments**

- Words in reg. 4(1) substituted (31.12.2020 immediately before IP completion day) by The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1306), regs. 1, 26(a)
- Words in reg. 4(1)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1306), regs. 1, 26(b)
- **F3** Words in reg. 4(1)(b) substituted (31.12.2020 immediately before IP completion day) by The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1306), regs. 1, 26(b)

#### **Commencement Information**

I1 Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

# **Changes to legislation:**

There are currently no known outstanding effects for the The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2019, PART 4.